Replies to post #489299 on Anavex Life Sciences Corp (AVXL)

[Hoskuld]

Why aren't you simply focused on longs winning instead of shorts losing? Shorts are generally institutional, smart, and hedged. They have a rich feed ground here among pre-commercial biopharma companies - then they move on when those companies actually have a marketable product. No big deal. This is the eco-system. You cannot beat the shorts - and that is, to my mind, OK. My investment is about winning to the upside - which is much higher than any gains to the downside over the long run (if Anavex succeeds.)

You seem to think I am rooting for the shorts. I am not. But, I have been in the pre-revenue biopharma game for since my mid-20s and can acknowledge the reality on the ground. It is a fantasy to think that there are huge number of shorts that will "get their comeuppance." Sure, an extremely small retail shorts will lose in a big way, but none of the usual suspects will have more than a tiny scratch (and they will keep their years of gains made to date.)

[Doc328]

"I still believe that the PD short selling was baked in -- preplanned -- to kill any PD trial rally. It remains their modus operandi today."

Actually, the bigger short during June was Missling, he sold almost 6 million shares between May and August. I do agree that Missling preplanned this and 5 PRs in 2 weeks both important and unimportant (similar to how he released a flurry just in time to set a better price for his option exercise in 2024). This did work out well as AVXL needed the cash (would have worked out better if he sold 20 MM shares) but the issuance of more shares kept a lid on the price.